FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310108045> ?p ?o ?g. }

• W4310108045 endingPage "8379" @default.
• W4310108045 startingPage "8378" @default.
• W4310108045 abstract "During SARS-CoV-2 infection, a severe hypercoagulability state is observed due to the stimulus of multiple mechanisms of hemostasis, such as intrinsic and extrinsic coagulation pathways, activation of platelets, endothelial cells, monocytes and neutrophils endothelial and impaired fibrinolysis. As a consequence, thrombotic complications are common in the course of COVID-19. Microvesicles (MVs) are intracellular transmitters that participate in pathological conditions, such as inflammatory and infectious processes, and are capable of triggering prothrombotic mechanisms. Since MVs release is potentially associated with COVID-19-induced coagulopathy, our aim was to identify the moment during the time course of the disease when the stimulus for MVs release occurs and whether this was associated with adverse outcomes. Therefore, we evaluate changes in MVs markers levels during the first month of SARS-CoV-2 infection in patients with severe disease (patients hospitalized in an intensive care unit - ICU) as compared to outpatients. We also evaluated the association between MVs markers and: acute phase inflammatory biomarkers (C-reactive protein, CRP), hypercoagulability (D-dimer) and death. Blood samples of patients were collected on three occasions: before the 10th day of symptoms (6th to 10th day), in the third week of symptoms (16th to 20th) and in the fourth week of symptoms (21st to 25th day) for the quantification of the following MVs markers by flow cytometry: CD41A (platelet activation), CD162 (PSGL-1; leukocyte-platelet interaction), CD31 (endothelium-platelet interaction) and CD142 (tissue factor). Statistical tests of ANOVA with repeated measures, Mann-Whitney and regression methods were used. The population studied was 85 patients, 65 outpatients and 20 ICU patients. Forty-three were men (51%), with a median age of 41 years old. The concentration of MVs expressing CD31+, CD41+, CD162+ and CD142+ were persistently elevated in patients who required ICU compared to outpatients at the 3 moments studied, except for the levels of MVs-CD31+ and MVs-CD142+ that were similar between ICU and outpatients in the fourth week of symptoms. However, despite the differences between the groups, there were no significant changes in the concentration of MVs during the course of the disease within the groups. In subgroup analysis, we observed that increases in the levels of MVs-CD162+ and MVs-CD142+ in the third week of symptoms were associated with the risk of death (P=0.02 and P=0.06, respectively). We also observed that before the 10th day of symptoms there was no correlation between MVs markers, CRP and D dimer levels. However, throughout the course of the disease the association between MVs, coagulability and inflammation was evident. In the third week of symptoms, D-dimer levels were correlated with MV-CD31+ (r=0.52; P<0.0001), MV-CD162+ (r=0.35, P=0.001), MV-CD41A+ (r=0.44, P<0.0001) and MV-CD142+ (r=0.47, P<0.0001). In the fourth week of symptoms, these correlations remained unchanged. CRP values from the third week of symptoms were correlated with MV-CD31+ (r=0.56, P=<0.0001), MV-CD162+ (r=0.48, P<0.0001), MV-CD41A+ (r= 0.41, P=0.0001), and MV-CD142+ (r=0.56, P<0.0001). In the fourth week of symptoms, these correlations remained unchanged. In conclusion, MVs that express antigens related to platelet activation, leukocyte-platelet interaction and endothelium-platelet interaction, as well as those related to tissue factor are released during the course of COVID-19 in patients with severe disease. After the 4th week of symptoms, the release of these MVs was associated with signs of inflammation and hypercoagulability. Additionally, MVs that express tissue factor and leukocyte-platelet interaction antigens were particularly high among non-survivors, suggesting that these MVs may serve as markers of the risk of death. Finally, these findings suggest the participation of innate immunity and tissue factor pathways in the prognosis of COVID-19, and point towards a possible role of MVs as biomarkers of disease prognosis. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310108045 created "2022-11-30" @default.
• W4310108045 creator A5001065311 @default.
• W4310108045 creator A5019023796 @default.
• W4310108045 creator A5020822553 @default.
• W4310108045 creator A5022531380 @default.
• W4310108045 creator A5060277143 @default.
• W4310108045 creator A5061791779 @default.
• W4310108045 creator A5071780133 @default.
• W4310108045 creator A5081635380 @default.
• W4310108045 creator A5087486860 @default.
• W4310108045 creator A5088143475 @default.
• W4310108045 date "2022-11-15" @default.
• W4310108045 modified "2023-09-30" @default.
• W4310108045 title "Extracellular Vesicles As Markers of Inflammation and Hypercoagulability during the First Month of Sars-COV-2 Infection in Outpatients and Hospitalized Patients" @default.
• W4310108045 doi "https://doi.org/10.1182/blood-2022-168977" @default.
• W4310108045 hasPublicationYear "2022" @default.
• W4310108045 type Work @default.
• W4310108045 citedByCount "0" @default.
• W4310108045 crossrefType "journal-article" @default.
• W4310108045 hasAuthorship W4310108045A5001065311 @default.
• W4310108045 hasAuthorship W4310108045A5019023796 @default.
• W4310108045 hasAuthorship W4310108045A5020822553 @default.
• W4310108045 hasAuthorship W4310108045A5022531380 @default.
• W4310108045 hasAuthorship W4310108045A5060277143 @default.
• W4310108045 hasAuthorship W4310108045A5061791779 @default.
• W4310108045 hasAuthorship W4310108045A5071780133 @default.
• W4310108045 hasAuthorship W4310108045A5081635380 @default.
• W4310108045 hasAuthorship W4310108045A5087486860 @default.
• W4310108045 hasAuthorship W4310108045A5088143475 @default.
• W4310108045 hasBestOaLocation W43101080451 @default.
• W4310108045 hasConcept C159047783 @default.
• W4310108045 hasConcept C203014093 @default.
• W4310108045 hasConcept C2776914184 @default.
• W4310108045 hasConcept C2992929900 @default.
• W4310108045 hasConcept C71924100 @default.
• W4310108045 hasConcept C86803240 @default.
• W4310108045 hasConcept C95444343 @default.
• W4310108045 hasConceptScore W4310108045C159047783 @default.
• W4310108045 hasConceptScore W4310108045C203014093 @default.
• W4310108045 hasConceptScore W4310108045C2776914184 @default.
• W4310108045 hasConceptScore W4310108045C2992929900 @default.
• W4310108045 hasConceptScore W4310108045C71924100 @default.
• W4310108045 hasConceptScore W4310108045C86803240 @default.
• W4310108045 hasConceptScore W4310108045C95444343 @default.
• W4310108045 hasIssue "Supplement 1" @default.
• W4310108045 hasLocation W43101080451 @default.
• W4310108045 hasLocation W43101080452 @default.
• W4310108045 hasOpenAccess W4310108045 @default.
• W4310108045 hasPrimaryLocation W43101080451 @default.
• W4310108045 hasRelatedWork W1567876945 @default.
• W4310108045 hasRelatedWork W1571778651 @default.
• W4310108045 hasRelatedWork W1924649133 @default.
• W4310108045 hasRelatedWork W2316013418 @default.
• W4310108045 hasRelatedWork W2562364476 @default.
• W4310108045 hasRelatedWork W2767759144 @default.
• W4310108045 hasRelatedWork W2903223704 @default.
• W4310108045 hasRelatedWork W2905584395 @default.
• W4310108045 hasRelatedWork W2945783588 @default.
• W4310108045 hasRelatedWork W3208137657 @default.
• W4310108045 hasVolume "140" @default.
• W4310108045 isParatext "false" @default.
• W4310108045 isRetracted "false" @default.
• W4310108045 workType "article" @default.